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cardiac arrest is a rare occurrence, the clear implication of our
data is that contemporary marathon race medical preparation
with advanced life support (including rapid access to defibril-
lation) is life-saving. Successful defibrillations in both marathon
events used manually operated defibrillators and rapid response
teams that often included physicians, paramedics, and emer-
gency medical technicians. Defibrillators and operators were
placed in fixed medical aid stations at two- to three-mile
intervals along the race route, at the finish line, and in mobile
ambulances. Both marathons also currently deploy mobile
first-response teams equipped with automatic external defibril-
lators moving along the race course with the runners on bicycles
and in golf carts to facilitate access to defibrillation. In addition,
race personnel are equipped with cell phones and short-wave
radios for alerting the medical teams should a runner collapse.
Indeed, it is our experience that the major determinant of
survival from cardiac arrest during the marathon is the proxim-
ity of a defibrillator to a collapsed runner.
In conclusion, marathon road racing, although increasing in
popularity and participation, is associated with a low (and decreas-
ing) risk for sudden cardiac death largely because of the availability
of advanced life support and timely defibrillation. That risk over
the last 10 years is only 1 in 220,000 race participants. These
observations offer an important measure of reassurance to potential
marathon participants and underscore the power of rapid defibril-
lation after cardiac arrest for enhancing the safety of sports
competition.
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Letters to the Editor
Cardiac Transplant Following
Failed Fontan or Glenn Procedures
It is with great interest that we read the study by Jayakumar et
al. (1) on the outcome following cardiac transplantation after a
failed Fontan or Glenn procedure. Because adults and children
were included in the study population, it is difficult to draw
meaningful comparisons to posttransplant survival data. Nev-
ertheless, in the more recent era of overall pediatric and adult
cardiac transplantation (1994 to 1998). International Society for
Heart and Lung Transplantation (ISHLT) Kaplan-Meier sur-
vival rates are reported at 80% and 82% at one year and 74% and
70% at five years’ posttransplant, respectively (2,3). In this
context, patient survival with cardiac transplantation after a
failed Fontan procedure, reported by Jayakumar et al. as 63% at
one year, and 57% at five years, is of concern (1). The
investigators have reported five-year combined survival rates in
both groups (post-Fontan and post-Glenn) in a later era
(1996–2001) as 77%, but it would be useful to report the
posttransplant survival in the failed Fontan patients separately
in this later period as these patients seem to have a worse
outcome than those transplanted after a Glenn procedure. The
majority of deaths occurred within seven days after transplan-
tation, and they were due to hemorrhage, multiorgan failure,
sepsis, and right ventricular failure. The increased mortality
Table 2. Clinical Data for Cardiac Events Occurring in Nine Marathon Runners
Cardiac Event Age/Gender Year Marathon Cardiovascular Disease
No. Prior
Marathons Circumstances of Collapse
Nonfatal cardiac arrest
1 46 M 1994 MC CAD — Mile #8
2 54 M 1996 MC CAD 1 Mile #21 (aid station)*
3 28 M 2000 TC Mitochondrial myopathy 1 At finish line†
4 52 M 2003 TC CAD 3 100 meters before finish
Sudden cardiac death
5 32 M 1986 MC CAD 3 Mile #15
6 40 M 1989 TC CAD 0 15 min after completing race†
7 19 F 1990 MC Anomalous LMCA 0 Mile #24
8 58 M 1993 MC CAD 3 Mile #23
9 54 M 2000 MC CAD‡ 1 Mile #2
*Evaluated for excessive fatigue; documented to have acute myocardial infarction. †Completed race in 4.5 h. ‡Previous coronary artery bypass grafting (three arteries).
CAD  atherosclerotic coronary artery disease; F  female; M  male; LMCA  left main coronary artery; MC Marine Corps Marathon; TC  Twin Cities Marathon.
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posttransplant in the failed Fontan physiology patients might be
due to various reasons.
First, an accurate determination of pulmonary vascular resis-
tance is difficult in the failed Fontan patient population because of
methodological inaccuracies that are implicit in the use of assumed
oxygen consumption. Pretransplant pulmonary hypertension even
in this modern era has consistently been a risk factor for poor
outcomes.
Second, in our experience cardiac cirrhosis of the liver can occur
especially in adults with failed Fontan physiology. Cardiac cirrho-
sis is variably encountered in adults with long-standing right heart
failure and can be insidiously present and difficult to diagnose in
the post-Fontan population owing to overlapping symptoms and
signs attributable to the failed Fontan state, such as ascites, pleural
effusions, and hypoproteinemia (4). Abdominal imaging studies
such as computed tomography and ultrasound are useful in making
the diagnosis by demonstrating a nodular liver. In selected cases,
liver biopsy may be needed because the outcome of heart trans-
plantation in patients with heart failure and dysfunction due to
passive congestion of the liver is best determined by the extent of
hepatic fibrosis demonstrated by histology (5).
Moreover, patients with significant cirrhosis have abnormal
coagulation profiles, are prone to infections, and can suffer from
hepatic decompensation postoperatively, thus adversely impacting
survival following heart transplantation. It is therefore important
to recognize the concept of cardiac cirrhosis and seek it in the
failed Fontan patient who is being considered for heart transplan-
tation. This may enable not only risk stratification but also, in
severe cases, consideration of aggressive approaches such as com-
bined heart and liver transplantation to help improve posttrans-
plant survival in these high-risk patients.
*Naveen L. Pereira, MD, FACC
Girish Shirali, MD, FACC
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REPLY
We appreciate the thoughtful comments from Drs. Pereira and
Shirali on our recent article (1) and would like to take this
opportunity to respond.
The power to detect significant differences in posttransplant
survival between the Fontan patients and other etiologies was
limited by the small number of Fontan patients (n  24), and
further subanalyses by type of surgery and era of transplant were
not feasible. Congenital heart disease has consistently been iden-
tified as a risk factor for one-year mortality according to reports of
the International Society for Heart and Lung Transplantation (2).
The majority of patients with congenital heart disease undergoing
transplantation have complex disease and single-ventricle physiol-
ogy. Similar to our data, conditional survival after one year was not
significantly different for the congenital heart disease patients
compared to others.
Pulmonary resistance is often impossible to determine in this
group of single-ventricle patients with multiple sources of
pulmonary blood flow; however, mortality from right heart
failure was not a cause of death in our series, except in the single
patient who had undergone a Fontan takedown procedure for
pulmonary hypertension. It is difficult to imagine that a patient
who is surviving, even poorly, with Fontan physiology would
have significant enough pulmonary hypertension leading to
right heart failure following implantation of a two-ventricle
heart.
Long-standing hepatic venous congestion was common
among patients in our series. The mean pretransplant pro-
thrombin time was 14.6  2 s, with a range of 11 to 18 s and
an international normalized ratio of 1.7  0.7, with a range of
1 to 2.9. There was no difference in the preoperative coagula-
tion profile among the three patients who died from hemor-
rhage and the other Fontan patients. Subtle abnormalities of
coagulation may have been present in these patients; however,
other causes of postoperative hemorrhage such as prolonged
cardiopulmonary bypass time and perfusion injury to the liver
may also have played a role.
Additional data from multicenter registries, such as the
Pediatric Heart Transplant Study Group, will soon be avail-
able that allows further risk stratification for posttransplant
outcome in these complex patients, and continued efforts to
define the criteria for transplantation are essential (3). We
appreciate the opportunity to respond to the letter by Drs.
Pereira and Shirali.
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